Table 2.
Vaccination effectiveness (VE) for hospitalization, mechanical intubation, and death.
| Hospitalization | Mechanical Ventilation | Death | ||||
|---|---|---|---|---|---|---|
| Effectiveness | Adjusted OR (95%CI) | Effectiveness | Adjusted OR (95%CI) | Effectiveness | Adjusted OR (95%CI) |
|
| At least one vaccine | 71% | 0.29 (0.19–0.45) |
98% | 0.02 (0.002–0.30) |
73% | 0.27 (0.09–0.87) |
| Incomplete Scheme | 67% | 0.33 (0.18–0.62) |
94% | 0.06 (0.002–1.71) |
- | - |
| Complete Scheme | 73% | 0.27 (0.17–0.43) |
99% | 0.01 (0.001–0.24) |
90% | 0.10 (0.02–0.44) |
| AstraZeneca AZD1222 (AstraZeneca/Oxford University) |
84% | 0.16 (0.08–0.30) |
99% | 0.002 (0.00007–0.07) | 91% | 0.09 (0.01–0.55) |
| Sputnik V Gam-COVID-Vac (Gamaleya Institute) | 81% | 0.19 (0.09–0.42) |
99% | 0.004 (0.00005–0.35) | 98% | 0.02 (0.001–0.42) |
| Pfizer BNT162b2 (Pfizer Inc/BioNTech) |
79% | 0.21 (0.10–0.44) |
98% | 0.02 (0.0008–0.97) |
95% | 0.05 (0.008–0.35) |
| CanSino Ad5-nCoV (CanSino Biologics) |
6% | 0.94 (0.31–2.8) |
- | - | - | - |
| SinoVac CoronaVac (SinoVac Research and Development Co) |
19% | 0.81 (0.35–1.9) |
98% | 0.02 (0.003–1.11) |
- | - |